From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...
Scientists have developed a new chimeric antibody that suppresses malignant cancers in dogs, showing promise for safe and effective treatment of intractable cancers. Similar to our aging society, dogs ...
Prospective Randomized Trial of Melphalan and Prednisone Versus Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Primary Systemic Amyloidosis PURPOSE: To ...
Antibody engineering enables the generation of novel and diverse antibody constructs. The development of therapeutic antibodies is highly dependent on antibody engineering, whether for the generation ...
Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer ...
The "Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com’s offering. The Global Cancer Monoclonal Antibody Partnering Terms and ...
Researchers from Nitrase Therapeutics Inc. recently presented preclinical findings on NTX-101, a murine chimeric antibody designed to specifically bind to nitrated tyrosine on α-synuclein (α-Syn). It ...
In 1975, Georges Köhler and César Milstein, biochemists from the Medical Research Council Laboratory of Molecular Biology, published a paper in Nature about a hybridoma technology that enabled the ...
RICHMOND, Calif.--(BUSINESS WIRE)--Accurus Biosciences Inc. (“Accurus”) is pleased to announce that it has entered into a worldwide licensing agreement for its CLDN18.2 monoclonal antibody with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results